"Biogen Inc. said its investigational therapy for the early stage of Alzheimer’s disease was granted fast-track designation by the U.S. Food and Drug Administration, a designation intended to bring promising drugs for serious conditions to market faster." marketwatch.com/story/biogen-shares-rise-after-fda-fast-tracks-alzheimers-treatment-2016-09-01 this news with a positive earnings may see that the stock continues to move higher this quarter. If the near term resistance line is not overcome a short position may be entered, but the reversal in the CMF on positive news may prove to support a higher move.